Aug 11, 2014
By Jane Brown
There is a renewed connection between breast cancer and hormone replacement therapy. The Canadian Cancer Society’s top epidemiologist has released a new report citing overwhelming evidence to a causal connection between the use of Premplus and the development of invasive breast cancer in women. According to Prithwish De’s report, hormone replacement therapy was the main risk factor in an estimated 12,000 new Canadian breast cancer cases detected between 1994 and 2006 at a time when Premarin and Premplus made by Wyeth Canada, dominated the market.
The report is to be filed in a Canadian class action lawsuit against the drug manufacturer, which is now owned by Pfizer. The drug manufacturer states its products are “safe and effective when used as directed” and they do not cause breast cancer. In recent years, the drugs have contained strong warnings and are also prescribed in lower doses. A trial date is set for October in a Vancouver court.